BRAF and melanoma: Although the treatment like the combination of BRAF inhibitor and MEK inhibitor or monoclonal anti-PD-1 antibody has increased the 5-year survival from less than 5% to approximately 30% (4), the prognosis of patients with advanced melanomas remains unoptimistic.